SS Innovations International (NASDAQ: SSII) has reported substantial growth in the utilization of its SSi Mantra surgical robotic system, with cumulative procedures reaching 14,103 as of Sept. 8, 2026, a 79% increase from 7,885 at the end of 2025. The installed base of the system also rose 42% to 238 units, up from 168. This expansion underscores the company's progress in making robotic surgery more accessible and affordable globally.
The SSi Mantra is now installed in 12 countries, and approximately 1,500 physicians have been trained on the platform, which has been used for more than 170 types of surgical procedures. Recent international milestones include the launch of robotic cardiac surgery in Colombia, the installation of the first SSi Mantra in Sri Lanka, and the first telesurgery within the Philippines. These developments highlight the system's versatility and its growing acceptance in diverse healthcare markets.
Additionally, SS Innovations reported 258 cumulative pediatric robotic surgeries and 188 robotic telesurgeries as of Aug. 31, including a telesurgery performed over a distance of more than 13,600 miles between Colombia and India. In August, five SSi Mantra systems were used to complete 50 robotic general surgery procedures in a single day in India, demonstrating the system's efficiency and reliability in high-volume settings.
Looking forward, the company expects the U.S. Food and Drug Administration to complete its review of the SSi Mantra 510(k) premarket notification by the end of the first quarter of 2027. It also believes European Union CE marking certification can be obtained by year-end 2026. These regulatory milestones are critical for SS Innovations' expansion into major markets, potentially opening doors to the U.S. and European healthcare systems, which represent significant opportunities for revenue growth and broader adoption.
The implications of these announcements are far-reaching. The rapid increase in procedures and installations indicates strong demand for cost-effective robotic surgery solutions, particularly in emerging markets where access to advanced surgical technologies has been limited. By training a large number of physicians and supporting a wide range of procedures, SS Innovations is building a robust ecosystem around its platform. The focus on telesurgery also positions the company at the forefront of remote surgical care, which could revolutionize healthcare delivery in underserved regions.
Moreover, the anticipated regulatory approvals could serve as catalysts for further growth. FDA clearance would allow SS Innovations to compete in the lucrative U.S. market, while CE marking would enable sales across the European Union. These certifications would not only validate the safety and efficacy of the SSi Mantra but also enhance the company's credibility and attract potential partnerships or investments.
For more details, the full report is available at https://ibn.fm/DJILj. The latest news and updates relating to SSII can be found in the company's newsroom at https://ibn.fm/SSII.
